145 related articles for article (PubMed ID: 35305461)
1. Design and development of photoswitchable DFG-Out RET kinase inhibitors.
Xu Y; Gao C; Andreasson M; Håversen L; Carrasco MP; Fleming C; Lundbäck T; Andréasson J; Grøtli M
Eur J Med Chem; 2022 Apr; 234():114226. PubMed ID: 35305461
[TBL] [Abstract][Full Text] [Related]
2. Design, Synthesis and Inhibitory Activity of Photoswitchable RET Kinase Inhibitors.
Ferreira R; Nilsson JR; Solano C; Andréasson J; Grøtli M
Sci Rep; 2015 May; 5():9769. PubMed ID: 25944708
[TBL] [Abstract][Full Text] [Related]
3. Characterization of interactions and pharmacophore development for DFG-out inhibitors to RET tyrosine kinase.
Gao C; Grøtli M; Eriksson LA
J Mol Model; 2015 Jul; 21(7):167. PubMed ID: 26044359
[TBL] [Abstract][Full Text] [Related]
4. Role of RET protein-tyrosine kinase inhibitors in the treatment RET-driven thyroid and lung cancers.
Roskoski R; Sadeghi-Nejad A
Pharmacol Res; 2018 Feb; 128():1-17. PubMed ID: 29284153
[TBL] [Abstract][Full Text] [Related]
5. Systematic Analysis of Tyrosine Kinase Inhibitor Response to RET Gatekeeper Mutations in Thyroid Cancer.
Meng S; Wu H; Wang J; Qiu Q
Mol Inform; 2016 Oct; 35(10):495-505. PubMed ID: 27712045
[TBL] [Abstract][Full Text] [Related]
6. Identification of Novel Small Molecule Inhibitors of Oncogenic RET Kinase.
Moccia M; Liu Q; Guida T; Federico G; Brescia A; Zhao Z; Choi HG; Deng X; Tan L; Wang J; Billaud M; Gray NS; Carlomagno F; Santoro M
PLoS One; 2015; 10(6):e0128364. PubMed ID: 26046350
[TBL] [Abstract][Full Text] [Related]
7. Fragment-Based Discovery of a Dual pan-RET/VEGFR2 Kinase Inhibitor Optimized for Single-Agent Polypharmacology.
Frett B; Carlomagno F; Moccia ML; Brescia A; Federico G; De Falco V; Admire B; Chen Z; Qi W; Santoro M; Li HY
Angew Chem Int Ed Engl; 2015 Jul; 54(30):8717-21. PubMed ID: 26126987
[TBL] [Abstract][Full Text] [Related]
8. Alectinib shows potent antitumor activity against RET-rearranged non-small cell lung cancer.
Kodama T; Tsukaguchi T; Satoh Y; Yoshida M; Watanabe Y; Kondoh O; Sakamoto H
Mol Cancer Ther; 2014 Dec; 13(12):2910-8. PubMed ID: 25349307
[TBL] [Abstract][Full Text] [Related]
9. 1-Methyl-3-((4-(quinolin-4-yloxy)phenyl)amino)-1H-pyrazole-4-carboxamide derivatives as new rearranged during Transfection (RET) kinase inhibitors capable of suppressing resistant mutants in solvent-front regions.
Zhang Y; Chan S; He R; Liu Y; Song X; Tu ZC; Ren X; Zhou Y; Zhang Z; Wang Z; Zhou F; Ding K
Eur J Med Chem; 2022 Dec; 244():114862. PubMed ID: 36308779
[TBL] [Abstract][Full Text] [Related]
10. Identification of nicotinamide aminonaphthyridine compounds as potent RET kinase inhibitors and antitumor activities against RET rearranged lung adenocarcinoma.
Wang M; Naganna N; Sintim HO
Bioorg Chem; 2019 Sep; 90():103052. PubMed ID: 31226468
[TBL] [Abstract][Full Text] [Related]
11. Discovery of N-Trisubstituted Pyrimidine Derivatives as Type I RET and RET Gatekeeper Mutant Inhibitors with a Novel Kinase Binding Pose.
Zhang L; Moccia M; Briggs DC; Bharate JB; Lakkaniga NR; Knowles P; Yan W; Tran P; Kharbanda A; Wang X; Leung YK; Frett B; Santoro M; McDonald NQ; Carlomagno F; Li HY
J Med Chem; 2022 Jan; 65(2):1536-1551. PubMed ID: 35081714
[TBL] [Abstract][Full Text] [Related]
12. Targeting Rearranged during Transfection in Cancer: A Perspective on Small-Molecule Inhibitors and Their Clinical Development.
Saha D; Ryan KR; Lakkaniga NR; Acharya B; Garcia NG; Smith EL; Frett B
J Med Chem; 2021 Aug; 64(16):11747-11773. PubMed ID: 34402300
[TBL] [Abstract][Full Text] [Related]
13. Discovery of 3,5-diaryl-1H-pyrazol-based ureas as potent RET inhibitors.
Wu K; He R; Li Z; Qiu K; Xiao G; Peng L; Meng X; Zheng C; Zhang Z; Cai Q
Eur J Med Chem; 2023 May; 251():115237. PubMed ID: 36905915
[TBL] [Abstract][Full Text] [Related]
14. EGF Induced RET Inhibitor Resistance in CCDC6-RET Lung Cancer Cells.
Chang H; Sung JH; Moon SU; Kim HS; Kim JW; Lee JS
Yonsei Med J; 2017 Jan; 58(1):9-18. PubMed ID: 27873490
[TBL] [Abstract][Full Text] [Related]
15. Sorafenib functions to potently suppress RET tyrosine kinase activity by direct enzymatic inhibition and promoting RET lysosomal degradation independent of proteasomal targeting.
Plaza-Menacho I; Mologni L; Sala E; Gambacorti-Passerini C; Magee AI; Links TP; Hofstra RM; Barford D; Isacke CM
J Biol Chem; 2007 Oct; 282(40):29230-40. PubMed ID: 17664273
[TBL] [Abstract][Full Text] [Related]
16. Photoswitchable Azo- and Diazocine-Functionalized Derivatives of the VEGFR-2 Inhibitor Axitinib.
Heintze L; Schmidt D; Rodat T; Witt L; Ewert J; Kriegs M; Herges R; Peifer C
Int J Mol Sci; 2020 Nov; 21(23):. PubMed ID: 33255816
[TBL] [Abstract][Full Text] [Related]
17. Recent developments of RET protein kinase inhibitors with diverse scaffolds as hinge binders.
Jia CC; Chen W; Feng ZL; Liu ZP
Future Med Chem; 2021 Jan; 13(1):45-62. PubMed ID: 33242992
[No Abstract] [Full Text] [Related]
18. Discovery and optimization of selective RET inhibitors via scaffold hopping.
Luo Z; Wang L; Fu Z; Shuai B; Luo M; Hu G; Chen J; Sun J; Wang J; Li J; Chen S; Zhang Y
Bioorg Med Chem Lett; 2021 Sep; 47():128149. PubMed ID: 34058344
[TBL] [Abstract][Full Text] [Related]
19. Identification of a novel 5-amino-3-(5-cyclopropylisoxazol-3-yl)-1-isopropyl-1H-pyrazole-4-carboxamide as a specific RET kinase inhibitor.
Yoon H; Shin I; Nam Y; Kim ND; Lee KB; Sim T
Eur J Med Chem; 2017 Jan; 125():1145-1155. PubMed ID: 27814560
[TBL] [Abstract][Full Text] [Related]
20. Development of RET kinase inhibitors for targeted cancer therapy.
Mologni L
Curr Med Chem; 2011; 18(2):162-75. PubMed ID: 21110809
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
